Abstract:Background Thorough QTc (TQT) studies using Electrocardiogram (ECG) data, are a well-established method for testing the pro-arrhythmic propensity of drugs performed during safety studies as part of drug development. ECG analysis is currently reduced to simplified biomarkers, such as rate, intervals and amplitudes. However, ECG waveforms are complex and generally sampled with high fidelity (125-1000 Hz). Our novel mathematical method, Symmetric Projection Attractor Reconstruction (SPAR) analyses the morphology and variability of such waveforms, using every data point to generate a new, faithful 2D waveform representation termed an 'attractor'. Moxifloxacin is a reversible blocker of the rapid component of the delayed rectifier, potassium current of the cardiac IKr potassium channel and has been shown to cause a mean increase of the QTc interval of 10–14 ms after an oral single dose of 400 mg. Separately, studies have shown that meals can alter QT interval as well as altering the pharmacokinetic profile of moxifloxacin itself with gender and ethnicity impacting individual responses. In-depth knowledge of these physiological factors could support safer medicines development and clinical use. Purpose This project investigated the feasibility of SPAR analysis of ECG signals to detect drug induced changes which a higher degree of sensitivity, to support safety evaluation during medicines development. Methods High resolution triplicate 12 lead ECG time-series data from a Phase one study of healthy human volunteers cross over of placebo, moxifloxacin or moxifloxacin + food was retrospectively analysed using SPAR. Using a bespoke software tool was used to perform SPAR analyses to transform ECG time-series into corresponding attractors. Corresponding single point measurements were previously obtained as part of the original Phase one study. Results Initial evaluation of attractors revealed high inter-individual variation, consistent with previous SPAR ECG analysis. Nevertheless, we identified changes in subjects receiving Moxifloxacin (six hour time point) when compared to those receiving placebo control. These changes were not as evident in previously obtained QT intervals. Conclusion This pilot study illustrates that SPAR is highlighting changes on the ECG that are less obvious from QT data alone. Further evaluation of the whole dataset to identify generalisable SPAR features, and their comparison with existing markers is now necessary. The individualised nature of ECGs and corresponding attractors indicates the method may have highest utility in personalised medicine, evaluating each individual's change and hence individual risk to drug induced arrhythmia.Visualisations of SPAR analysis of ECGs

Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics

Inhibition by fluoroquinolones of K+ currents in rat dissociated hippocampal neurons

Fluoroquinolone-induced torsade de pointes

Modulation of the Late Sodium Current by ATX-II and Ranolazine Affects the Reverse Use-Dependence and Proarrhythmic Liability of IKrblockade

Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation

Contribution of cytokine-mediated prolongation of QTc interval to the multi-hit theory of Torsade de Pointes

QTc interval prolongation complicated by torsade de pointes induced by amiodarone and moxifloxacin: a case report

Advanced waveform analysis of the electrocardiogram signals using complementary signal processing techniques to investigate the response to a QTc prolonging drug vs control

GW24-e2999 Proarrhythmic window of a drug determines the risk of multiple ion channel inhibitors

Role of Late Sodium Current in Modulating the Proarrhythmic and Antiarrhythmic Effects of Quinidine.

Optimized J to T peak and T peak to T end measurements in nonclinical species administered moxifloxacin and amiodarone

Expanded activity and utility of the new fluoroquinolones: a review

An Updated Safety Review of the Relationship Between Atypical Antipsychotic Drugs, the QTc Interval and Torsades de Pointe As: Implications for Clinical Use

Insights into antibiotic resistance promoted by quinolone exposure

Blockage of hERG current and the disruption of trafficking as induced by roxithromycin.

Electrophysiologic Effects of SB-237376: a New Antiarrhythmic Compound with Dual Potassium and Calcium Channel Blocking Action.

Effects of inhibition of endogenous late sodium current on the reverse rate dependence and transmural dispersion of action potential duration prolongation by drugs that inhibit potassium currents

Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans

COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels

Concentration–response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent

Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review